Trinity boosts coagulation line as Sigma exits diagnostics
This article was originally published in Clinica
Executive Summary
Ireland's Trinity Biotech is to buy life science company Sigma-Aldrich's coagulation product line for an undisclosed amount. For Bray-based Trinity, the development continues its strategy, which it formed in 2001, to move into the $600m haemostasis market, while the deal follows Sigma's announcement earlier this year that it planned to exit diagnostics.